RE: Looking14 Jan 2020 13:58
16m free cashflow annually recurring for only 78 Clinical polarisers [multiples targeted post FDA to around 1000.]
Peeps may laugh at a £1 - see above.
I think its around here as POLX is not that widely followed - the investment case will permeate at some point - patented, no comp, growing health need, recurring rev model - think I might buy some more!!